Table of Contents Author Guidelines Submit a Manuscript
International Journal of Genomics
Volume 2014, Article ID 312130, 9 pages
http://dx.doi.org/10.1155/2014/312130
Research Article

High Expression of Polo-Like Kinase 1 Is Associated with Early Development of Hepatocellular Carcinoma

Department of Surgery, Shengjing Hospital, China Medical University, Sanhao Road, Shenyang 11004, China

Received 21 January 2014; Revised 9 April 2014; Accepted 10 April 2014; Published 11 June 2014

Academic Editor: Yong-Qing Wang

Copyright © 2014 Wei Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. A. Mesri, M. A. Feitelson, and K. Munger, “Human viral oncogenesis: a cancer hallmarks analysis,” Cell Host & Microbe, vol. 15, no. 3, pp. 266–282, 2014. View at Publisher · View at Google Scholar
  2. A. G. Vaiopoulos, K. C. Athanasoula, and A. G. Papavassiliou, “Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges,” Biochimica et Biophysica Acta, vol. 1842, no. 7, pp. 971–980, 2014. View at Publisher · View at Google Scholar
  3. S. L. Markant, L. A. Esparza, J. Sun et al., “Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases,” Cancer Research, vol. 73, no. 20, pp. 6310–6322, 2013. View at Publisher · View at Google Scholar
  4. C. E. Sunkel and D. M. Glover, “polo, a mitotic mutant of Drosophila displaying abnormal spindle poles,” Journal of Cell Science, vol. 89, pp. 25–38, 1988. View at Google Scholar · View at Scopus
  5. F. A. Barr, H. H. W. Silljé, and E. A. Nigg, “Polo-like kinases and the orchestration of cell division,” Nature Reviews Molecular Cell Biology, vol. 5, no. 6, pp. 429–440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. B. C. M. van de Weerdt and R. H. Medema, “Polo-like kinases: a team in control of the division,” Cell Cycle, vol. 5, no. 8, pp. 853–864, 2006. View at Google Scholar · View at Scopus
  7. F. Eckerdt, J. Yuan, and K. Strebhardt, “Polo-like kinases and oncogenesis,” Oncogene, vol. 24, no. 2, pp. 267–276, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Strebhardt and A. Ullrich, “Targeting polo-like kinase 1 for cancer therapy,” Nature Reviews Cancer, vol. 6, no. 4, pp. 321–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Caldwell and S. H. Park, “The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology,” Journal of Gastroenterology, vol. 44, no. 19, pp. 96–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. J. McMahon, “The natural history of chronic hepatitis B virus infection,” Hepatology, vol. 49, no. 5, pp. S45–S55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. A. Farazi and R. A. DePinho, “Hepatocellular carcinoma pathogenesis: from genes to environment,” Nature Reviews Cancer, vol. 6, no. 9, pp. 674–687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. B. Thomas, D. Jaffe et al., “Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting,” Journal of Clinical Oncology, vol. 28, pp. 3994–4005, 2010. View at Publisher · View at Google Scholar
  13. M. Sherman, “Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis,” Seminars in Liver Disease, vol. 30, no. 1, pp. 3–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. Z.-L. He, H. Zheng, H. Lin, X.-Y. Miao, and D.-W. Zhong, “Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients,” World Journal of Gastroenterology, vol. 15, no. 33, pp. 4177–4182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Chen and Q. Kong, “Evaluation of centrosome abnormalities and p53 inactivation in chemical induced hepatocellular carcinogenesis,” Neoplasma, vol. 56, no. 2, pp. 169–176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Takahashi, B. Sano, T. Nagata et al., “Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers,” Cancer Science, vol. 94, no. 2, pp. 148–152, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Ando, T. Ozaki, H. Yamamoto et al., “Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation,” Journal of Biological Chemistry, vol. 279, no. 24, pp. 25549–25561, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. Q. W. Xiao, Q. Z. Yong, K. S. Lui, Q. Cai, P. Lu, and R. T. Poon, “Aberrant polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma,” Clinical Cancer Research, vol. 14, no. 21, pp. 6813–6820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Tang, X. Yang, and X. Liu, “Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression,” Oncogene, vol. 27, no. 52, pp. 6635–6645, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Tsvetkov and D. F. Stern, “Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage,” Cell Cycle, vol. 4, no. 1, pp. 166–171, 2005. View at Google Scholar · View at Scopus
  21. X. Liu and R. L. Erikson, “Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5789–5794, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Spänkuch-Schmitt, G. Wolf, C. Solbach et al., “Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells,” Oncogene, vol. 21, no. 20, pp. 3162–3171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. N.-N. Kreis, K. Sommer, M. Sanhaji et al., “Long-term downregulation of polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21WAF1/CIP1,” Cell Cycle, vol. 8, no. 3, pp. 460–472, 2009. View at Google Scholar · View at Scopus
  24. I. Marzo, C. Brenner, N. Zamzami et al., “Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis,” Science, vol. 281, no. 5385, pp. 2027–2031, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. L. McKenzie, S. King, L. Marcar et al., “p53-dependent repression of polo-like kinase-1 (PLK1),” Cell Cycle, vol. 9, no. 20, pp. 4200–4212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Pellegrino, D. F. Calvisi, S. Ladu et al., “Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma,” Hepatology, vol. 51, no. 3, pp. 857–868, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. M. Soond, S. P. Barry, G. Melino, R. A. Knight, D. S. Latchman, and A. Stephanou, “p73-mediated transcriptional activity is negatively regulated by polo-like kinase,” Cell Cycle, vol. 7, no. 9, pp. 1214–1223, 2008. View at Google Scholar · View at Scopus